Lamellar Biomedical Raises £5.75m in Series C Funding
Summary
Lamellar Biomedical, a Bellshill, Scotland, UK-based biotechnology company developing a range of patent-protected medical and pharmaceutical products, raised £5.75m in Series C equity funding.The round was led by Invesco Asset Management Limited and supported by the Scottish Investment Bank (“SIB”), the investment arm of Scottish Enterprise.The company will use the funds to: – Support the commercialization of both Lamelleye and Visco-ease globally through partners – Generate clinical data with Muco-ease to position it for a potential co-development deal – Expand its pipeline of LAMELLASOME[TM] based pharmaceuticals targeting indications with high unmet medical needs including infection Led by Alec McLean, CEO, Lamellar is developing a pipeline of novel patent-protected medical devices and pharmaceuticals targeting: – Dry Eye Disease (DED) with Lamelleye – Radiotherapy-Induced Xerostomia (RIX) with Visco-ease – Cystic Fibrosis (CF) with Muco-ease The pipeline products target conditions that are poorly served by current medications and therefore represent areas of high value unmet medical need.FinSMEs 08/05/2017